TRI and MCC Integrate RBM Tools
The solution will ‘hand-hold’ companies through the process of performing a protocol risk assessment and developing resulting quality risk management plan.
Following a long-standing working relationship between Triumph Research Intelligence (TRI) and the Metrics Champion Consortium (MCC), TRI will make MCC’s Risk Assessment and Mitigation Management Tool (RAMMT) available as part of the risk assessment and management module in its OPRA Risk-Based Monitoring and Quality Management platform. The OPRA solution will ‘hand-hold’ companies through the process of performing a protocol risk assessment and developing resulting quality risk management plan in a centrally accessible, cloud based application, and provide the guidance which comes from the MCC’s RAMMT content at the same time.
Read the full release.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
